Advertisement
| biologic therapies for asthma: Severe Asthma Kian Fan Chung, Elliot Israel, Peter G. Gibson, 2019-06-01 Severe asthma is a form of asthma that responds poorly to currently available medication, and its patients represent those with greatest unmet needs. In the last 10 years, substantial progress has been made in terms of understanding some of the mechanisms that drive severe asthma; there have also been concomitant advances in the recognition of specific molecular phenotypes. This ERS Monograph covers all aspects of severe asthma – epidemiology, diagnosis, mechanisms, treatment and management – but has a particular focus on recent understanding of mechanistic heterogeneity based on an analytic approach using various ‘omics platforms applied to clinically well-defined asthma cohorts. How these advances have led to improved management targets is also emphasised. This book brings together the clinical and scientific expertise of those from around the world who are collaborating to solve the problem of severe asthma. |
| biologic therapies for asthma: Respiratory Disease in Pregnancy Stephen E. Lapinsky, Lauren A. Plante, 2020-04-09 Covers a broad spectrum of respiratory diseases during pregnancy, in order to improve successful management of both mother and fetus. |
| biologic therapies for asthma: Severe Asthma in Children and Adolescents Erick Forno, Sejal Saglani, 2019-11-13 This book provides readers with a comprehensive review of severe asthma in children and adolescents, covering epidemiology, genetics, risk factors, co-morbidities, clinical presentation, diagnosis and treatment. Written by leaders in the field, chapter discussions draw on the mechanisms driving the disease, genetics, multidisciplinary approaches, immunomodulators, and other important aspects in the management of the disease. Severe Asthma in Children and Adolescents: Mechanisms and Management is designed to be a practical guide, opening with an introduction on the epidemiology of severe childhood asthma, as well as a discussion of special considerations of the disease unique to the preschool-aged patient. The distinctions between the diagnosis and management of asthma in young children of various ages, and specific approaches for the adolescent with severe asthma, including the transition into adult care are then addressed. Finally, the book closes with a discussion on the current state and future avenues for severe asthma research. Severe Asthma in Children and Adolescents is an indispensable reference for the healthcare professional, for basic and translational researchers, as well as for students, residents and fellows. |
| biologic therapies for asthma: Advances in Asthma Akihito Yokoyama, 2018-12-18 This book provides discussions on bronchial asthma from a clinical perspective, focusing on the recent studies on its pathophysiology, diagnosis and treatment. It also explores the lastest findings regarding the phenotypes and endotypes of asthmatic patients, making it of particular interest to those involved with non-eosinophilic asthma and eosinophilic asthma. Further, it discusses the importance of ILC 2 in eosinophilic asthma, and the accumulated results from the forced oscilliation technique and periostin that are actively practiced in Japan. As some aspects of diagnosis and treatment are different in Western and Asian countries, it is important that the data is disseminated around the globe. The clinical questions addressed by the authors are critical and thought provoking, while the questions raised by the editors are instructive, informative and provide new perspectives on unresolved issues. This book appeals to wide readership from beginning learners to physicians in clinical practice and scholars engaging in basic research. |
| biologic therapies for asthma: Severe Asthma S. J. Szefler, Donald Y. M. Leung, 1996 Bridging the gap between basic science and clinical research, this comprehensive and fully up-to-date reference presents new directions in asthma care - examining the pathophysiology, epidemiology, immunology, environmental control, and psychosocial impact of severe asthma. |
| biologic therapies for asthma: Adverse Reactions to Biologics L. Puig, W. Gulliver, 2017-11-07 In many areas of medicine physicians still face the great challenge of finding therapies that will meet the patients’ needs. In dermatology the challenge has arisen on multiple fronts through advances in the understanding of the immunopathogenesis of many inflammatory and malignant cutaneous disorders. Breakthroughs, combined with significant developments in targeted immunotherapy, have resulted in improved outcomes as these newer therapies are being used for both approved indications and as off-label therapies for various chronic inflammatory skin disorders and many forms of skin cancer. In the expectation that by truly understanding the safety profile of these targeted therapies patients’ outcomes will be significantly improved, this book offers insights into topics such as adverse reactions, infectious complications and the perioperative use of biologics in psoriasis, immunogenicity of biologic therapies, paradoxical reactions, safety of biologics used to treat autoimmune bullous diseases and primary cutaneous lymphomas, adverse reactions and skin manifestations of therapies targeting melanoma and non-melanoma skin cancer and other neoplastic diseases. Eminent researchers with extensive clinical experience have contributed to this publication, providing an in-depth overview of the latest knowledge in this field. |
| biologic therapies for asthma: Personalizing Asthma Management for the Clinician Stanley J. Szefler, Fernando Holguin, Michael E Wechsler, 2017-09-22 Personalized medicine is a rapidly emerging area in health care, and asthma management lends itself particularly well to this new development. This practical resource by Dr. Stanley J. Szefler helps you navigate the many asthma medication options available to your patients, as well as providing insights into those which may be introduced within the next several years. - Features a wealth of information on available asthma medications, including new immunomodulators, new responses to treatment, and new treatment strategies at all levels of asthma care. - Prepares you to meet your patients' needs regarding asthma exacerbation prevention and asthma prevention. - Consolidates today's available information and guidance in this timely area into one convenient resource. |
| biologic therapies for asthma: Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems Kamal Dua, Philip M. Hansbro, Ridhima Wadhwa, Mehra Haghi, Lisa G. Pont, Kylie A. Williams, 2020-08-04 Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems explores the development of novel therapeutics and diagnostics to improve pulmonary disease management, looking down to the nanoscale level for an efficient system of targeting and managing respiratory disease. The book examines numerous nanoparticle-based drug systems such as nanocrystals, dendrimers, polymeric micelles, protein-based, carbon nanotube, and liposomes that can offer advantages over traditional drug delivery systems. Starting with a brief introduction on different types of nanoparticles in respiratory disease conditions, the book then focuses on current trends in disease pathology that use different in vitro and in vivo models. The comprehensive resource is designed for those new to the field and to specialized scientists and researchers involved in pulmonary research and drug development. - Explores recent perspectives and challenges regarding the management and diagnosis of chronic respiratory diseases - Provides insights into how advanced drug delivery systems can be effectively formulated and delivered for the management of various pulmonary diseases - Includes the most recent information on diagnostic methods and treatment strategies using controlled drug delivery systems (including nanotechnology) |
| biologic therapies for asthma: Chronic Rhinosinusitis Wytske J. Fokkens, 2009 This issue will focus on treatments for Chronic Rhinosinusitis. Dr. Wyste Fokkens guest edits topics such as: Inflammatory mechanisms in chronic rhinosinusitis with or without nasal polyposis, European versus Asian Chronic rhinosinusitis. What did it teach us and what do we want to know, Epithelium, cilia and mucus, their importance in chronic rhinosinusitis Noam Cohen Noam, Aspirin intolerance: does desensitization alter the course of the disease, Anti-inflammatory effects of macrolides: applications in CRS, and more! |
| biologic therapies for asthma: Difficult To Treat Asthma Sandhya Khurana, Fernando Holguin, 2019-08-29 This book provides a practical, stepwise, evidence-based approach to effective management of patients with difficult to treat asthma. The impact of asthma on morbidity and healthcare utilization increases exponentially with severity. Severe refractory asthma accounts for less than 5% of all asthma. Its prevalence, however, is often overestimated as there are several other confounding factors that make asthma ‘difficult to treat’. Many novel (albeit expensive) therapies are now available and providers caring for patients with severe asthma are charged with selecting the best evidence treatment. This calls for complex and nuanced decision-making. Whether people with asthma gain and maintain control over their condition depends not only on the availability of effective drugs, but also multiple patient and healthcare provider behaviors. Therefore, now more than ever, it has become increasingly important to differentiate “difficult” from “severe refractory” asthma to allow identification of patients most likely to benefit from these therapies. This volume delves into the current understanding of mechanisms and increasingly recognized heterogeneity of this complex disease. It discusses a structured approach to identification and optimization of factors contributing to poor asthma control, including nonadherence, comorbidities and occupational/environmental triggers. The book includes ‘state of the art’ reviews on recent advances in traditional and targeted asthma therapies, as well as a glimpse into what the future may hold. Highlights include a comprehensive guide to management of severe asthma in children and pregnancy, as well as practical considerations to management of asthma based on different clinical phenotypes. Each chapter is authored by leading experts in the field who share their own clinical approach. This is an ideal guide for clinical pulmonologists and allergist/immunologists, as well as primary care providers, physician extenders in specialty practice, physicians in pulmonary/allergy training, and even industry partners. |
| biologic therapies for asthma: Safe and Effective Medicines for Children Institute of Medicine, Board on Health Sciences Policy, Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), 2012-10-13 The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children. |
| biologic therapies for asthma: Immunotherapy in Asthma Jean Bousquet, Hans Yssel, 1999-08-24 This massive reference thoroughly analyzes the mechanisms implicated in the pathophysiology of asthma, such as T helper lymphocyte subsets, and the consequences of various extrinsic and intrinsic factors, and IgE receptor expression-reviewing current concepts in immunotherapeutic approaches for the treatment of this and other allergic diseases. Investigates the only category of treatment showing the potential to affect the natural course of allergic diseases and prevent the onset of asthma. Written by more than 80 internationally renowned pulmonary experts, allergic disease specialists, and basic researchers, Immunotherapy in Asthma discusses the efficacy of new medications examines the role of metachromatic cells, lymphocytes, macrophages, and other cell types present in bronchial biopsies presents basic topics such as the functional and phenotypic properties of Th1 and Th2 cells and their role in allergic disease and the regulation of IgE-mediated inflammatory responses addresses the deleterious effects of smoking and passive exposure to cigarette smoke in children and adults assesses differences and similarities between intrinsic and antigen-induced asthma describes the effects of immunogenic peptides on the cytokine production profile of allergen-specific CD4+ T cells explains the different clinical aspects of allergic responses, such as bronchial hyperreactivity and eosinophilic inflammation of the airways reviews the genetic basis of allergy, as well as risk factors for asthma explores oral, sublingual, local nasal, and local bronchial routes for noninjective immunotherapies evaluates various agents with modulatory effects on normal and pathogenic immune responses focuses on strategies for the prevention of childhood asthma and more! Containing over 3000 references, drawings, and tables, Immunotherapy in Asthma is an indispensable resource for pulmonologists, immunologists, allergists, and medical school students in these disciplines. |
| biologic therapies for asthma: Immune Mediated Diseases Michael R Shurin, Yuri S. Smolkin, 2007-09-23 This volume includes contributions from the speakers of the Second IMD Congress (September 10-15, 2007; Moscow, Russia) who were eager to share some of the academic and clinical enthusiasm that defines the IMD meetings. The goal of the International Immune-Mediated Diseases: From Theory to Therapy (IMD) Congress is to bring the world’s best immunologists and clinicians to Moscow. |
| biologic therapies for asthma: 2019 Pocket Guide for Asthma Management Global Initiative For Asthma, 2019-04-10 The Global Strategy for Asthma Management and Prevention provides a comprehensive and integrated approach to asthma management that can be adapted for local conditions and for individual patients. It focuses not only on the existing strong evidence base, but also on clarity of language and on providing tools for feasible implementation in clinical practice. The report is updated each year. The 2019 GINA report includes important new recommendations for treatment of mild asthma (page 16) and severe asthma (page 24). |
| biologic therapies for asthma: Allergy and Asthma , 2019-06-25 Allergy and Asthma: The Basics to Best Practices is intended to serve as a single comprehensive reference covering all needed knowledge of allergic diseases. Allergy is a unique and distinctive area of medicine wherein learning the fundamentals requires gathering information from various different disciplines. Allergic diseases affect various organ systems and the practice of a wide range of physicians from otolaryngologists, and pulmonologists, to gastroenterologists, dermatologists, and ophthalmologists. Clinicians and trainees alike will benefit from a resource that introduces the basic concepts, as well as providing comprehensive, consistently up-to-date instruction on intermediate and advanced conditions, research, and treatment strategies. The book is divided into nine sections and is written by some of the foremost experts in the field. Allergy and Asthma opens with an introduction which covers the epidemiology of allergic diseases, fundamentals of allergy and immunology, and a thorough grounding of different types of allergens. Early sections address allergic upper airway diseases, allergic skin diseases, and asthma in detail, using a structured, consistent format from chapter to chapter to provide continuity and ease of reference. Later sections thoroughly cover various food allergies, insect allergies, drug allergy, anaphylaxis, and utilize ample tables and illustrations to provide additional learning tools for the reader. This major reference not only provides basic knowledge on diagnosing and treating allergies, but moves beyond these basics to emphasize using a systematic approach to working up and treating a patient. A variety of techniques used in diagnosing asthma and allergy will be examined, of which include prick skin tests, in-vitro testing, patch testing and non-conventional allergy tests. Concluding this book are sections dedicated to management, therapeutic strategies of allergy and asthma, with a look to future research directions for this unique field. Physicians and residents in allergy and immunology, pulmonology, otolaryngology, gastroenterology, dermatology, ophthalmology and other specialties will find the work of value in enhancing their practice and studies. Researchers in a range of areas especially immunology and food science will also find this text to be a compelling and reliable resource. |
| biologic therapies for asthma: Asthma: Targeted Biological Therapies Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli, 2016-11-10 This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma. |
| biologic therapies for asthma: Eosinophils in Health and Disease James J. Lee, Helene F. Rosenberg, 2012-11-02 Eosinophils in Health and Disease provides immunology researchers and students with a comprehensive overview of current thought and cutting-edge eosinophil research, providing chapters on basic science, disease-specific issues, therapeutics, models for study and areas of emerging importance. |
| biologic therapies for asthma: Asthma Celso Pereira, 2019-10-02 Asthma is a prevalent disease in all age groups that results from different pathogenic mechanisms, cells, and mediators engaged in innumerous clinical phenotypes and endotypes. This book exhaustively and didactically explores the biological expression of numerous cells and mediators involved in bronchial inflammation. The information provided aims at identifying the diversity and complexity of the interrelationships between the different players, drawing attention to critical mechanisms in asthma. It also highlights the requirement of new tools to identify strong biomarkers absolutely critical for managing asthma. |
| biologic therapies for asthma: Hemoperfusion, Plasmaperfusion And Other Clinical Uses Of General, Biospecific, Immuno And Leucocyte Adsorbents Thomas Ming Swi Chang, Yoshihiro Endo, Volodymyr G Nikolaev, Tohru Tani, Yaoting Yu, Wen Hui Zheng, 2017-02-17 Written by 30 worldwide leading scientists, experts and medical doctors, this comprehensive book provides a broad, multi-disciplinary overview on hemoperfusion. The research of the subject was started by TMS Chang — the pioneer and inventor of microcapsules who is well known as the 'the Father of Microcapsules.' The book presents the numerous recent developments in this field. A series of tailor-made, toxin removing and cell separating adsorbents or microcapsules with unique properties have been designed, prepared and produced for use in the treatment of diseases such as autoimmune disease, drug over-dose, acute inflammation, etc., in which ordinary medical treatments shows little or no efficacy. Various modalities of hemoperfusion treatments and results are described to provide readers with up-to-date information on the highly interdisciplinary field of hemoperfusion. |
| biologic therapies for asthma: Airway Remodeling Peter Howarth, John William Wilson, Jean Bousquet, Sabina Rak, Romain Pauwels, 2001 This landmark volume discusses the characteristics and impact of the remodeling process on airway function and clinical disease expression within the airway in asthma, covering pharmacological therapies and possible future targets relevant to regulating the remodeling process. Emphasizes the importance of treating underlying airway inflammation and the relevance of structural alterations to the airway wall, including glandular increases, enhanced collagen deposition within the submucosa, increased vasculature, smooth hypertrophy, and hyperplasias! Tracing the development and maintenance of bronchial hyperresponsiveness, decline in lung function, and loss of reversibility evident in chronic asthma, Airway Remodelingdescribes the contribution of inflammatory cells in the development of airway structural changes examines how pharmaceutical agents act and whether existing treatments modify or prevent remodeling in chronically inflamed asthmatic airways considers whether neural pathways initiate as well as contribute to the airway inflammatory cascade that leads to remodeling reviews the action of cytokines and growth factors on ASM signaling outlines novel approaches to regulating smooth muscle growth clarifies whether permanent ventilatory incapacity in asthma is caused by the uncoupling of the airway and the role of the lung parenchyma details high-resolution computerized tomography scan to measure the internal size of the airway at baseline, during challenge, or after bronchodilatation and more!Improving lung function and quality of life by reducing the need for emergency care, hospital admissions, and systemic steroid administration, Airway Remodeling is a superb reference for pulmonologists and respiratory system specialists; physiologists; pneumologists; allergists; pharmacologists; molecular, cellular, and lung biologists; and graduate and medical school students in these disciplines. |
| biologic therapies for asthma: Tourism In India- Status, Challenges And Opportunities Prof. Manoj Srivastava , Dr. Sidharth Shankar Raju , Dr. Gaurav Bhattacharya, 2021-10-21 Dr. Manoj Srivastava is a PhD from Manipal University Jaipur.Over three decades of experience in Hospitality Industry & Academia, Food Production Research,resulting made9 culinary based Limca Book of World Records. For which he is honored with Honorius Causa form England. He join the Hospitality Industry in 1990 when he joined the Taj Group of Hotels. He rose quickly to product development and research. Joined Australian Bakels as National Support Manager. At Present associated as Professor& Principal,NIMS University, School of Hotel Management. He is authored a Book “The Art of research in Hospitality” and wrote many research papers in National and International journals of repute.He is on the board of many Journal as Editorial Board member & Reviewer of Hospitality & Tourism management journals. |
| biologic therapies for asthma: Biologic Therapies of Immunologic Diseases, An Issue of Immunology and Allergy Clinics of North America Bradley E. Chipps, Stephen P. Peters, 2017-04-12 This issue of Immunology and Allergy Clinics, guest edited by Drs. Bradley Chipps and Stephen Peters, is devoted to Biologic Therapies of Immunologic Diseases. Articles in this issue include: Immunologic Mechanisms and Potential Targets; Strategies for Immunologic Interventions; Patient Characteristics and Individualization of Therapy; Biologic Therapies for Autoimmune and Connective Tissue Diseases; Biologic Therapies for Skin Disease including Urticaria; Biologic Therapies for Asthma; Biologic Therapies for Rhinitis and Sinusitis; Biologic Therapies for Chronic Obstructive Pulmonary Disease; Biologic Therapies for Food Allergies and Eosinophilic Esophagitis; Future Prospects for Biologic Therapies of Immunologic Diseases; Pharmacoeconomics of Biologic Therapy; and Adverse Reaction to Biologic Therapy. |
| biologic therapies for asthma: British Guideline on the Management of Asthma , 2008 |
| biologic therapies for asthma: MRI of the Lung Hans-Ulrich Kauczor, 2008-11-12 During the past decade significant developments have been achieved in the field of magnetic resonance imaging (MRI), enabling MRI to enter the clinical arena of chest imaging. Standard protocols can now be implemented on up-to-date scanners, allowing MRI to be used as a first-line imaging modality for various lung diseases, including cystic fibrosis, pulmonary hypertension and even lung cancer. The diagnostic benefits stem from the ability of MRI to visualize changes in lung structure while simultaneously imaging different aspects of lung function, such as perfusion, respiratory motion, ventilation and gas exchange. On this basis, novel quantitative surrogates for lung function can be obtained. This book provides a comprehensive overview of how to use MRI for imaging of lung disease. Special emphasis is placed on benign diseases requiring regular monitoring, given that it is patients with these diseases who derive the greatest benefit from the avoidance of ionizing radiation. |
| biologic therapies for asthma: Antibiotics as Anti-Inflammatory and Immunomodulatory Agents Bruce K. Rubin, Jun Tamaoki, 2005-02-14 Although the potential for immunomodulation has been recognized for many years there has been an explosion of data in this field with relevance especially to the treatment of chronic airway diseases. Most of the work in this field has been conducted by Japanese investigators but in the last decade there has been a body of work outside of Japan that supports and enhances these findings. The book covers basic research like effects on bacteria, anti-inflammatory and mucoregulatory effects, but also clinical results with up-to-date information for the use of such medications to potentially treat diseases as diverse as chronic airway diseases, arthritis, inflammatory bowel disease, and cancer. The volume is intended for pulmonary physicians, researchers in inflammation research, and pharmaceutical companies interested in the development of such agents. It provides background information for the clinician as well as in depth exploration of cutting edge science. |
| biologic therapies for asthma: Childhood Asthma Stanley J Szefler, Soren Pedersen, 2005-09-26 This reference collects the latest studies on the development, diagnosis, and treatment of childhood asthma and offers current perspectives on new technologies that will shape the management of pediatric asthma in the forthcoming decade-illustrating how advances in pulmonary function measurement, inflammatory markers, imaging, and pharmacogenetics |
| biologic therapies for asthma: Current Review of Asthma Michael A. Kaliner, 2002-12-09 This comprehensive source of up-to-date information on asthma diagnosis and treatment offers concise discussions on concomitant diseases and treatment choices. Coverage includes epidemiology, pathology, airway remodeling, and pathophysiology. Each chapter offers a topic overview, followed by an analysis of current understanding, supplemented by charts, tables, and graphs. Dr. Michael A. Kaliner, the editor, contributes a chapter, The Pathogenesis of Bronchial Asthma, drawing on his 30 years of clinical experience. |
| biologic therapies for asthma: Asthma Adherence , 1999 |
| biologic therapies for asthma: Cells of the Immune System Ota Fuchs, Seyyed Shamsadin Athari, 2020-05-13 The cells of the immune system are lymphocytes (T-cells, B-cells and NK (natural killer) cells), neutrophils, eosinophils, and monocytes/macrophages. This book is an overview of some types of these cells and their role in recognizing and/or reacting against foreign material. The immune system is characterized by collaboration between cells and proteins. The development of all cells of the immune system begins in the bone marrow with a hematopoietic stem cell. Two chapters deal with neutrophils, three chapters with T-cells, four chapters with eosinophils, and other chapters review the immunomodulation of macrophages, the role of transcription factor KLF4 in regulating plasticity of myeloid-derived suppressor cells, immune reconstitution after allogeneic hematopoietic stem cell transplantation, and role of sorption detoxification in the therapy of acute radiation sickness. |
| biologic therapies for asthma: Middleton's Allergy E-Book A Wesley Burks, Robyn E. O'Hehir, David H. Broide, Stephen T Holgate, Leonard B. Bacharier, Gurjit K. Khurana Hershey, R. Stokes Peebles, 2019-09-25 Through eight outstanding editions, Middleton's Allergy: Principles and Practice has been the reference of choice for both clinicians and researchers as both a practical reference and an effective self-assessment tool for board preparation. The 9th Edition continues the tradition of excellence with comprehensive coverage of all basic science and clinical applications regarding allergy practice and disease mechanisms. It brings you fully up to date with recent innovations in the diagnosis, prevention, and management of allergic disorders, including emerging global issues, the advent of precision medicine, and new immunologic therapies. - Offers unparalleled depth and up-to-date guidance on the full spectrum of allergy across the lifespan, with significant updates throughout. - Contains new chapters on Innate Lymphoid Cells, Systems Biology, and Treatment of Primary Immunodeficiency Diseases. - Discusses emerging topics such as epidemic thunderstorm asthma and precision medicine in allergic disorders. - Features more than 730 full-color illustrations, including many new cellular and molecular drawings of disease mechanisms. - Includes new Summary of Important Concepts boxes, plus new multiple-choice questions online with explanations and answers. - Features a new team of expert editors and more international contributors for a global perspective of this complex field. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. |
| biologic therapies for asthma: The Asthmas Vibeke Backer, Peter G. Gibson, Ian D. Pavord, 2022-09-05 The field of asthma has expanded in the last decade with specific drugs targeting the disease mechanisms. This book is an updated treatise covering diagnoses, phenotypes and endotypes of asthma along with its management. It includes diagnostic work-up which is required prior to medical assistance and basic immunology assessment, illustrating the types, severity, number of exacerbations due to disease activity, allergy or infections. As the treatment selection has changed from one size fits all to precision-based medicine, it aims to refine asthma management with right medication usage, neither overuse nor underuse, and initiation of the new hospital administered biologic drugs. Key Features • Covers both respiratory physiology and airway inflammation • Highlights the use of biologic drugs • Discusses precision-based medicine • Explores the comorbidities through clinical cases |
| biologic therapies for asthma: Inhaled Medicines Stavros Kassinos, Per Bäckman, Joy Conway, Anthony J. J. Hickey, 2021-02-05 Inhaled medicines are widely used to treat pulmonary and systemic diseases. The efficacy and safety of these medicines can be influenced by the deposited fraction, the regional deposition pattern within the lungs and by post-depositional events such as drug dissolution, absorption and clearance from the lungs. Optimizing performance of treatments thus requires that we understand and are able to quantify these product and drug attributes. Inhaled Medicines: Optimizing Development through Integration of In Silico, In Vitro and In Vivo Approaches explores the current state of the art with respect to inhalation drug delivery, technologies available to assess product performance, and novel in silico methods now available to link in vitro product performance to clinical performance. Recent developments in the latter field, especially the prospect of integration of three-dimensional Computational Fluid Particle Methods (3D-CFPD) with physiologically based pharmacokinetic (PBPK models), unlocks the potential for in silico population studies that can help inform and optimize treatment and product development strategies. In this highly multidisciplinary field, where progress occurs at the intersection of several disciplines of engineering and science, this work aims to integrate current knowledge and understanding and to articulate a clear vision for future developments. ? Considers the healthcare needs driving the field, and where inhaled drugs could have the maximum impact ? Gives a concise account of the state of the art in key areas and technologies such as device and formulation technologies, clinically relevant in vitro performance assessment, medical imaging, as well as in silico modelling and simulation ? Articulates how the combination of in vitro product performance data, medical imaging and simulations technologies in the framework of large scale in silico pre-clinical trials could revolutionize the field ? Provides systematic and thorough referencing to sources offering a more-in-depth analysis of technical issues |
| biologic therapies for asthma: Human Eosinophils Gianni Marone, 2000 Eosinophils represent approximately 1% of peripheral blood leukocytes and play a central proinflammatory and immunoregulatory role in various immune disorders. This volume provides the reader with a comprehensive survey of the major aspects of human eosinophilic biology and immunology as well as the most clinically relevant aspects of eosinophil-related disorders. Expert contributions cover the ultrastructural and phenotypic characteristics of human eosinophils, and their fundamental biochemical features including receptors for IgE and chemokines. The production of cytokines and their role in the activation of eosinophils are reviewed. Furthermore, the classic eosinophil-related disorders such as hypereosinophilia, drug reactions, allergic disorders and some cardiovascular diseases are described. Each of the chapters is written by an investigator actively engaged in research on the topic under consideration. The well-edited and stimulating material compiled in this volume will be of interest to all those working in allergology, immunology, biochemistry and pulmonary medicine. |
| biologic therapies for asthma: Civetta, Taylor, & Kirby's Critical Care Andrea Gabrielli, A. Joseph Layon, Mihae Yu, Joseph M. Civetta, Robert Wesley Taylor, Robert R. Kirby, 2009 Now in its fourth edition, this leading critical care textbook contains more than 30 new chapters and completely updated information. The book addresses every problem encountered in the intensive care unit and covers surgical critical care more thoroughly than any other text. |
| biologic therapies for asthma: Nocturnal Asthma Peter J. Barnes, Jonathan Levy, 1984 |
| biologic therapies for asthma: Clinical Aspects of Immunology D. K. Peters, P. J. Lachmann, M. J. Walport, 1992-12-31 |
| biologic therapies for asthma: Immunopharmacology David J Webb, 2013-02-18 This new volume of Advances in Pharmacology explores the current state of Alzheimer's disease research and therapeutics. Chapters cover such topics as the B cell targeted therapies, Lymphotoxin family receptors in inflammation, and allergic inflammation and thymic stromal lymphopoietin. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike. - Explores the current state of Alzheimer's disease research and therapeutics - Chapters cover a variety of topics such as the B cell targeted therapies, lymphotoxin family receptors in inflammation, and allergic inflammation and thymic stromal lymphopoietin - With the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike |
| biologic therapies for asthma: Biologics for the Treatment of Allergic Diseases, An Issue of Immunology and Allergy Clinics of North America, E-Book Lanny J. Rosenwasser, 2020-10-15 This issue of Immunology and Allergy Clinics, guest edited by Dr. Lanny Rosenwasser, will provide up-to-date clinical concepts regarding Biologics for the Treatments of Allergic Conditions. Articles in this outstanding issue include: Allergic Rhinitis/CRS/Polyposis, Eosinophilic Asthma, Pediatric Asthma, Severe Asthma, ACOS/COPD, Food Allergy, Atopic Dermatitis, Chronic Urticaria, Anaphylaxis, Drug Allergy, Cell Disorders, Biologics and Immunotherapy, and much more. |
| biologic therapies for asthma: Biologics in Otolaryngology, An Issue of Otolaryngologic Clinics of North America, E-Book Sarah K. Wise, Ashkan Monfared, Nicole Schmitt, 2021-07-09 This issue of Otolaryngologic Clinics, guest edited by Drs. Sarah K. Wise, Ashkan Monfared, and Nicole C. Schmitt is devoted to Biologics in Otolaryngology. This issue is one of six selected each year by our series consulting editor, Dr. Sujana S. Chandrasekhar. Articles in this issue include: Biologics in otolaryngology overview, Current evidence for biologic therapy in chronic rhinosinusitis with nasal polyposis, Choosing the right patient for biologic therapy in CRSwNP, Knowledge gaps and research needs for biologic therapy in rhinology practice, Mechanisms and practical use of biologic therapies for allergy and asthma indications, Immunotherapeutic strategies in head and neck cancer, Cetuximab in head and neck cancer, Anti-PD-1 immune checkpoint blockade for head and neck cancer, Advances in adoptive cell therapy for head and neck cancer, Biologics for the treatment of recurrent respiratory papillomatosis, Past and future biologics for otologic disorders, Biological treatments for Neurofibromatosis Type II and other skullbase disorders, and Biologics in treatment of autoimmune ear disorders. |
| biologic therapies for asthma: Biologics in Allergic/Immunologic Conditions, An Issue of Immunology and Allergy Clinics of North America Flavia Hoyte, 2024-10-14 In this issue of Immunology and Allergy Clinics, guest editor Dr. Flavia Hoyte brings her considerable expertise to the topic of Biologics in Allergic/Immunologic Conditions. Top experts provide an overview of the state of biologic treatments for autoimmune and allergic conditions including asthma, COPD, food allergies, atopic dermatitis; and more. - Contains 13 relevant, practice-oriented topics including current and emerging biologics in CSU; biologics in AERD and ABPA; and multiple articles on biologics in asthma, including the role of biomarkers, the potential to achieve clinical remission, real-world studies, emerging biologics; and more. - Provides in-depth clinical reviews on biologics in allergic/immunologic conditions, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews. |
Biologic Therapies for Severe Asthma - The New England …
Jan 13, 2022 · Airway Inflammation in Severe Asthma and Targets of Biologic Therapies. The inflammatory pathways of type 2 high-inflammation (type 2–high) asthma (Panel A) or type 2 …
Biologic Therapies for Treatment of Asthma Associated with …
This project will evaluate the health and economic outcomes of five biologic therapies for asthma: omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab.
Choosing the Right Biologic for the Right Patient With Severe …
With six biologics now approved for use in this area comprising four different targeting strategies (anti-Ig E: omali-zumab; anti-IL-5 and anti-IL-5-receptor: mepolizumab, reslizumab, and …
Head-to-Head Effectiveness Comparison of Biological …
For patients with severe asthma, 40% to 80% have both allergic and eosinophilic phenotypes (severe mixed asthma [SMA]). There are no head-to-head studies of biologic therapies in this …
Biologic treatments for severe asthma - uhsussex.nhs.uk
Biologic treatments for asthma are also called monoclonal antibodies. They are lab-created and aim to stop eosinophils from causing inflammation of the airways, excess mucus production …
Biological therapy for severe asthma - BioMed Central
To date, four types of biologics are licensed for severe asthma, i.e. omalizumab (anti-immunoglobulin E) antibody, mepolizumab and reslizumab (anti-interleukin [IL]-5antibody), …
Asthma Biologics
There are currently six biologic therapies for asthma that offer diverse mechanisms to enhance lung function, reduce exacerbation risk, and potentially decrease oral corticoste-roid …
The Role of Biologics in Severe Asthma Management: …
Biological therapies have significantly transformed the management of severe asthma, providing a targeted approach that addresses the underlying inflammatory mechanisms responsible for …
A comparison of the effectiveness of biologic therapies for …
randomized trials addressing biologic therapies for asthma. Reviewers worked independently and in duplicate to screen references, extract data, and assess risk of bias.
Asthma Biologics Programme - healthinnovationoxford.org
This programme covered four high-cost biologic treatments approved for patients with Severe Asthma from the start. These treatments are, Reslizumab, Benralizumab, Mepolizumab and …
The Role of Biologic Therapy in Severe Asthma: A Shifting …
v LO 1: Describe the current concepts in the pathophysiology of asthma and type 2 inflammation, and the implications of biologic therapies in the era of precision medicine v LO 2: Discuss the …
Biologic Therapies for Treatment of Moderate-to- Severe
Asthma Management with Biologic Therapies • Mepolizumab 100 mg by subcutaneous injection once every 4 weeks • Reslizumab 3 mg/kg by intravenous infusion once every 4 weeks
Biologics in severe asthma: A pragmatic approach for …
May 10, 2023 · Biologics which target T2 inflammatory pathways are highly effective in achieving asthma control and reducing risk of exacerbations in those patients with T2 inflammation …
Biologics and Personalized Medicine in Severe Asthma: One …
Biologic therapies represent a major advance in the treatment of difficult-to-treat severe asthma, providing a therapeutic option that is highly effective in reducing severe exacerbation risk in …
Effectiveness of Biologics in Asthma: Comparing Real-world …
moderate-to-severe asthma and comparing the efficacy of dupilumab with mepolizumab, benralizumab, omalizumab, reslizumab, or tezepelumab in reducing asthma exacerbation …
Biologic Therapies for the Treatment of Moderate-Severe …
The primary aim of this analysis was to estimate the cost-effectiveness of each of the five biologic agents for the treatment of moderate to severe uncontrolled asthma with evidence of type 2 …
Effect of biologic therapies on quality of life in severe asthma ...
Background: Anti-type 2 (T2) biologic therapies (biologics) improve exacerbation rates, lung function, and asthma-related quality of life (QoL) in patients with severe T2 asthma. However, …
How to Assess Effectiveness of Biologics for Asthma and …
Five biologic medications are approved in the United States for the treatment of asthma that is not well controlled with other therapies. All target asthma with elevated type 2 inflammatory …
Biologic Therapies for Treatment of Moderate-To- Severe
evaluation of biologic agents for the treatment of moderate-to-severe uncontrolled asthma with evidence of Type 2 inflammation. Refer to the research protocol for details on the systematic
Biologic Therapies for Treatment of Asthma Associated with …
Nov 13, 2018 · Evidence Report – Biologic Therapies for Treatment of Asthma . Executive Summary . Background . The Centers for Disease Control and Prevention (CDC) estimates …
Biologic Therapies for Severe Asthma - The New England …
Jan 13, 2022 · Airway Inflammation in Severe Asthma and Targets of Biologic Therapies. The inflammatory pathways of type 2 high-inflammation (type 2–high) asthma (Panel A) or type 2 …
Biologic Therapies for Treatment of Asthma Associated with …
This project will evaluate the health and economic outcomes of five biologic therapies for asthma: omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab.
Choosing the Right Biologic for the Right Patient With Severe …
With six biologics now approved for use in this area comprising four different targeting strategies (anti-Ig E: omali-zumab; anti-IL-5 and anti-IL-5-receptor: mepolizumab, reslizumab, and …
Head-to-Head Effectiveness Comparison of Biological …
For patients with severe asthma, 40% to 80% have both allergic and eosinophilic phenotypes (severe mixed asthma [SMA]). There are no head-to-head studies of biologic therapies in this …
Biologic treatments for severe asthma - uhsussex.nhs.uk
Biologic treatments for asthma are also called monoclonal antibodies. They are lab-created and aim to stop eosinophils from causing inflammation of the airways, excess mucus production …
Biological therapy for severe asthma - BioMed Central
To date, four types of biologics are licensed for severe asthma, i.e. omalizumab (anti-immunoglobulin E) antibody, mepolizumab and reslizumab (anti-interleukin [IL]-5antibody), …
Asthma Biologics
There are currently six biologic therapies for asthma that offer diverse mechanisms to enhance lung function, reduce exacerbation risk, and potentially decrease oral corticoste-roid …
The Role of Biologics in Severe Asthma Management: …
Biological therapies have significantly transformed the management of severe asthma, providing a targeted approach that addresses the underlying inflammatory mechanisms responsible for …
A comparison of the effectiveness of biologic therapies for …
randomized trials addressing biologic therapies for asthma. Reviewers worked independently and in duplicate to screen references, extract data, and assess risk of bias.
Asthma Biologics Programme - healthinnovationoxford.org
This programme covered four high-cost biologic treatments approved for patients with Severe Asthma from the start. These treatments are, Reslizumab, Benralizumab, Mepolizumab and …
The Role of Biologic Therapy in Severe Asthma: A Shifting …
v LO 1: Describe the current concepts in the pathophysiology of asthma and type 2 inflammation, and the implications of biologic therapies in the era of precision medicine v LO 2: Discuss the …
Biologic Therapies for Treatment of Moderate-to- Severe
Asthma Management with Biologic Therapies • Mepolizumab 100 mg by subcutaneous injection once every 4 weeks • Reslizumab 3 mg/kg by intravenous infusion once every 4 weeks
Biologics in severe asthma: A pragmatic approach for …
May 10, 2023 · Biologics which target T2 inflammatory pathways are highly effective in achieving asthma control and reducing risk of exacerbations in those patients with T2 inflammation …
Biologics and Personalized Medicine in Severe Asthma: One …
Biologic therapies represent a major advance in the treatment of difficult-to-treat severe asthma, providing a therapeutic option that is highly effective in reducing severe exacerbation risk in …
Effectiveness of Biologics in Asthma: Comparing Real-world …
moderate-to-severe asthma and comparing the efficacy of dupilumab with mepolizumab, benralizumab, omalizumab, reslizumab, or tezepelumab in reducing asthma exacerbation …
Biologic Therapies for the Treatment of Moderate-Severe …
The primary aim of this analysis was to estimate the cost-effectiveness of each of the five biologic agents for the treatment of moderate to severe uncontrolled asthma with evidence of type 2 …
Effect of biologic therapies on quality of life in severe asthma ...
Background: Anti-type 2 (T2) biologic therapies (biologics) improve exacerbation rates, lung function, and asthma-related quality of life (QoL) in patients with severe T2 asthma. However, …
How to Assess Effectiveness of Biologics for Asthma and …
Five biologic medications are approved in the United States for the treatment of asthma that is not well controlled with other therapies. All target asthma with elevated type 2 inflammatory …
Biologic Therapies for Treatment of Moderate-To- Severe
evaluation of biologic agents for the treatment of moderate-to-severe uncontrolled asthma with evidence of Type 2 inflammation. Refer to the research protocol for details on the systematic
Biologic Therapies for Treatment of Asthma Associated with …
Nov 13, 2018 · Evidence Report – Biologic Therapies for Treatment of Asthma . Executive Summary . Background . The Centers for Disease Control and Prevention (CDC) estimates …
